Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | CES1 | P23141 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL4565150 | 0.93 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Salicylic Acid SCHEMBL4564953 | 0.91 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL2164112 | 0.82 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL195821 | 0.79 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL4506080 | 0.77 | ALDH1A1 (0.65) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL11233274 | 0.77 | ALDH1A1 (0.65) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL5604206 | 0.76 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL848649 | 0.76 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL7519717 | 0.76 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL1319085 | 0.76 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704101-B1 | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME | SERVIER LAB (FR) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025027075-A1 | COCRYSTAL OF AN IDH1 INHIBITOR, PROCESS OF PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING THE SAME | LES LABORATOIRES SERVIER (FR) | 2025-02-06 | — | — | WO | disclosed |
| US-20250041283-A1 | COCRYSTAL OF AN IDH1 INHIBITOR, PROCESS OF PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING THE SAME | SERVIER PHARMACEUTICALS LLC | 2025-02-06 | — | — | US | disclosed |
| US-20250034109-A1 | SALTS, COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING THE SAME | SERVIER PHARMACEUTICALS LLC | 2025-01-30 | — | — | US | disclosed |
| WO-2025021856-A1 | SALTS, COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING THE SAME | LES LABORATOIRES SERVIER (FR) | 2025-01-30 | — | — | WO | disclosed |
| US-20240343705-A1 | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME | SERVIER PHARMACEUTICALS LLC | 2024-10-17 | — | — | US | disclosed |
| US-11851417-B2 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | SERVIER PHARMACEUTICALS LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20220387618-A1 | METHODS OF TREATING HER2 POSITIVE BREAST CANCER WITH TUCATINIB IN COMBINATION WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE | SEAGEN INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220363661-A1 | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME | SERVIER PHARMACEUTICALS LLC | 2022-11-17 | — | — | US | disclosed |
| EP-4058024-A1 | METHODS OF TREATING HER2 POSITIVE BREAST CANCER WITH TUCATINIB IN COMBINATION WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE | Seagen Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-11345677-B2 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343705-A1 | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME | TP53, HCCS, LPXN | ALDH1A1 1848/4885KDM4E 1820/4885HPGD 461/4885 |
| US-20220363661-A1 | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME | TP53, HCCS, LPXN | ALDH1A1 1848/4885KDM4E 1820/4885HPGD 461/4885 |
| US-11851417-B2 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | TP53, HCCS, LPXN | ALDH1A1 1848/4885KDM4E 1820/4885HPGD 461/4885 |
| US-11345677-B2 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | TP53, HCCS, LPXN | ALDH1A1 1848/4885KDM4E 1820/4885HPGD 461/4885 |
| US-20220387618-A1 | METHODS OF TREATING HER2 POSITIVE BREAST CANCER WITH TUCATINIB IN COMBINATION WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE | ERBB2, EGFR, ERBB3 | ALDH1A1 2545/4885KDM4E 1914/4885HPGD 4026/4885 |
| US-20250041283-A1 | COCRYSTAL OF AN IDH1 INHIBITOR, PROCESS OF PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING THE SAME | IDH1, IDH3B, IDH3A | ALDH1A1 617/4885KDM4E 75/4885HPGD 163/4885 |
| US-20250034109-A1 | SALTS, COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING THE SAME | TP53, LPXN, SLC10A1 | ALDH1A1 1835/4885KDM4E 2119/4885HPGD 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.